FDAsafety guidance83% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Biogen.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Nephrology · Immunoglobulin A Nephropathy
- Sub-indication
- General
Related signal: Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults